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Abstract
The 2014–16 Ebola Virus Disease (EVD) outbreak in West Africa highlighted the necessity
for readily available, accurate and rapid diagnostics. The magnitude of the outbreak and the
re-emergence of clusters of EVD cases following the declaration of interrupted transmission
in Liberia, reinforced the need for sustained diagnostics to support surveillance and emer-
gency preparedness. We describe implementation of the Xpert Ebola Assay, a rapid molec-
ular diagnostic test run on the GeneXpert platform, at a mobile laboratory in Liberia and the
subsequent impact on EVD outbreak response, case management and laboratory system
strengthening. During the period of operation, site coordination, management and opera-
tional capacity was supported through a successful collaboration between Ministry of Health
(MoH), World Health Organization (WHO) and international partners. A team of Liberian lab-
oratory technicians were trained to conduct EVD diagnostics and the laboratory had capac-
ity to test 64–100 blood specimens per day. Establishment of the laboratory significantly
increased the daily testing capacity for EVD in Liberia, from 180 to 250 specimens at a time
when the effectiveness of the surveillance system was threatened by insufficient diagnostic
capacity. During the 18 months of operation, the laboratory tested a total of 9,063 blood
specimens, including 21 EVD positives from six confirmed cases during two outbreaks. Fol-
lowing clearance of the significant backlog of untested EVD specimens in November 2015,
a new cluster of EVD cases was detected at the laboratory. Collaboration between surveil-
lance and laboratory coordination teams during this and a later outbreak in March 2016,
facilitated timely and targeted response interventions. Specimens taken from cases during
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both outbreaks were analysed at the laboratory with results informing clinical management
of patients and discharge decisions. The GeneXpert platform is easy to use, has relatively
low running costs and can be integrated into other national diagnostic algorithms. The tech-
nology has on average a 2-hour sample-to-result time and allows for single specimen testing
to overcome potential delays of batching. This model of a mobile laboratory equipped with
Xpert Ebola test, staffed by local laboratory technicians, could serve to strengthen outbreak
preparedness and response for future outbreaks of EVD in Liberia and the region.
Author summary
We describe a model of a mobile laboratory co-located at an Ebola treatment unit (ETU)
equipped with GeneXpert molecular diagnostic platform and automated qRT-PCR test
for Ebola virus disease (EVD). The laboratory contributed significantly to the EVD
response in Liberia, including supporting surveillance, outbreak detection, contact tracing
and management of confirmed cases. The laboratory was run by local laboratory techni-
cians as opposed to international experts on short missions, making it a more sustainable
option in prolonged outbreaks and early recovery phases. The redeployment and strategic
placement of these GeneXpert instruments to complement EVD isolation facilities
throughout the country has strengthened preparedness and response capabilities for
future EVD outbreaks in Liberia.
Introduction
The Ebola Virus Disease (EVD) outbreak first declared in Guinea in March 2014, spread to
neighbouring countries Liberia and Sierra Leone and was declared a Public Health Emergency
of International Concern (PHEIC) on the 8th of August, 2014 [1]. This deadly outbreak
affected some of the least developed countries in the world, with already fragile health systems
and insufficient laboratory infrastructure and diagnostic capabilities [2–5]. An unprecedented
28,616 cases and 11,310 deaths were reported across all affected countries, of which nearly
11,000 cases and over 4,800 deaths were reported in Liberia [6]. Failures in diagnostic pre-
paredness, the unavailability of suitable rapid diagnostic tests, the weak surveillance system
leading to a delays in detecting cases and the limited therapeutic options for EVD, among
other factors, contributed to its rapid spread, and persistent transmission in the affected coun-
tries [7–11].
Most commonly, laboratory diagnosis of EVD is achieved by detection of viral RNA, by
real-time reverse transcription polymerase chain reaction (RT-PCR) and viral antigen detec-
tion tests [7, 12, 13]. Nucleic acid and viral antigen can be detected in blood within 3–10 days
after the onset of symptoms [7]. In addition to case confirmation, EVD laboratory data
informs contact tracing and emergency response interventions as well as patient management,
clinical treatment and discharge decisions [5, 7, 14].
In October 2014, World Health Organization (WHO) issued a target product profile (TPP)
for manufactures to develop rapid and easy to use point-of-care diagnostics [15] and an emer-
gency use authorisation (EUA) mechanism was established to review submissions [16]. Foun-
dation for Innovative New Diagnostics (FIND) worked collaboratively with The Emerging and
Dangerous Pathogens Laboratory Network (EDPLN), WHO and partners leading field evalua-
tions of novel in-vitro diagnostics [17, 18].
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Prior to 2014, laboratory diagnosis for EVD was not available in Liberia and very limited
expertise in molecular diagnostic techniques existed, only at the National Reference Labora-
tory (NRL) in Margibi County. Deployment of international support often as mobile laborato-
ries was critical to the management of the EVD outbreak throughout West Africa [5, 9, 17, 19–
21]. At the peak of the outbreak Liberia had ten operational EVD Laboratories supported by
international partners [22]. However, as the outbreak waned and specimen numbers declined,
international partners exited Liberia leaving only three operational laboratories by June 2015
[22]. These were located at the NRL, Margibi, Phebe Hospital, Bong and Tappita Hospital,
Nimba, with no EVD laboratory in the most densely populated Montserrado county where the
capital city Monrovia is located.
The magnitude of the outbreak and the re-emergence of clusters of EVD cases following
the declaration of interrupted transmission, highlighted the need for sustained EVD diagnos-
tics to support surveillance in Liberia [2, 5, 7]. Following the Margibi cluster in June 2015 [23,
24], Liberia entered a 90 day period of heightened surveillance. Subsequently, an unanticipated
increase in specimens taken from patients fitting the EVD outbreak suspect case definition
were received at the three operational laboratories between August-October 2015. Insufficient
laboratory diagnostic capacity, resulted in an inability to sustain real-time testing and a build-
up of untested specimens in the system. A number of measures were imposed to increase daily
EVD diagnostic capacity from 180 to approx. 250 specimens including; extended laboratory
hours of operation, training local laboratory technicians on molecular diagnostics and the
implementation of the Xpert Ebola Assay on the GeneXpert system.
The Xpert Ebola test, is an automated cartridge-based system for both RNA extraction and
RT-PCR detection of Ebola virus (EBOV), nucleoprotein (NP) and glycoprotein (GP) gene tar-
gets [7, 25–27]. The system is designed for the rapid testing of suspected and confirmed EVD
cases in health-care settings such as isolation facilities and Ebola Treatment Units (ETU) [7].
Xpert Ebola Assay is typically used for the detection of EBOV in whole blood samples and has
no detectable cross-reactivity with arboviruses or other haemorrhagic fever viruses [26, 28].
The result provides a cycle threshold (Ct) value for the RT-PCR, which has previously been
shown to inversely correlate with the quantity of viral target present in the specimen [19, 21,
26]. Low Ct values upon initial testing indicate high viral loads in patient samples and more
severe disease with a higher case fatality rate [7, 19, 21, 29–32].
The WHO included Cepheid’s Xpert Ebola Test to its list of Ebola diagnostics with EUA on
the 8th May 2015 and it received Food and Drug Association (FDA) approval in March 2015
[33, 34]. In September 2015, the Xpert Ebola Assay was approved by the Liberian Ministry of
Health (MoH), for use as a stand-alone diagnostic test for EVD in whole blood specimens.
With support from WHO, FIND, Academic Consortium to Combating Ebola in Liberia
(ACCEL), United States Centers for Disease Control and Prevention (CDC) and other stake-
holders, the Xpert Ebola Assay was instituted at a mobile laboratory, the Eternal Love Winning
Africa (ELWA) III Laboratory. We describe the establishment, operations and impact of the
ELWA III mobile laboratory over the 18-month period of operation.
Methods
Ethics statement
This public health intervention was part of the Ebola outbreak response in Liberia and was a
humanitarian project approved by the Ministry of Health (MoH), Liberia and resourced and
supported by a collaboration of international partners. Data analysis was performed on exist-
ing, anonymized datasets that had been previously analysed and reported through the estab-
lished MoH laboratory EVD results reporting system. Secondary analysis of pre-existing,
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anonymized data did not require ethical review and approval by the Liberia National Research
Ethics Board (NREB).
Establishment and coordination of the mobile laboratory
The mobile laboratory structures described here were donated to the MoH following the
departure of international partners (Dutch Mobile Lab) in early 2015. In August 2015 WHO
and CDC logistics teams facilitated the transfer of the mobile containers from Sinje, Grand
Cape Mount county, approximately 32 kilometres / 20 miles to be located at ELWA ETU in
Montserrado county, the only remaining functional ETU in Liberia.
The mobile unit consisted of three separate containers; the laboratory unit, a storage unit
and an office. The layout of the laboratory is represented in Fig 1. A sample reception area was
erected in front of the laboratory and roofing was constructed to cover this area and the con-
tainers to protect against harsh weather conditions. The laboratory container was pre-fitted
with a glove box and filters, ventilation system, an uninterrupted power supply (UPS), a refrig-
erator and an air-conditioning unit.
Laboratory coordination
Fig 2 shows the timeline of key events in establishing and running the ELWA III mobile EVD
testing laboratory from conceptualisation and operationalisation of the laboratory in 2015 to
testing of the last specimens in October 2016 and eventual closure in March 2017. Under the
coordination of MoH and WHO, the project was successfully implemented through a collabo-
rative framework involving a number of key laboratory stakeholders; MoH, WHO, ACCEL,
FIND, eHealth Africa, Riders for Health (RFH) and US CDC. WHO and ACCEL provided
oversight and coordination including technical guidance, logistic support, staff management,
training and data management during the 18-month operational period described.
Operational logistics
The ELWA III laboratory provided diagnostics for specimens collected at the ELWA ETU as
well as surveillance specimens collected from Montserrado county and the surrounding areas.
In the initial months of operation the laboratory also acted as surge capacity for the other three
EVD testing laboratories where the number of specimens being received for testing was higher
than the daily testing capacity. Transport of specimens to the ELWA III laboratory was facili-
tated by RFH, the established specimen transportation system in Liberia. RFH is a is an inter-
national non-profit organisation that provides innovative solutions for specimen transport in
many African countries from rural health facilities to diagnostics centres using motorcycles
[35].
Four GeneXpert instruments (each with a 4-module configuration) were installed within
the laboratory container along with a shared laptop, individual power stabilisers and bench
shields. Three instruments were donated by FIND and one by ACCEL as part of EVD response
efforts in Liberia. The Xpert Ebola Assay kits (50 tests each) were provided by FIND and
WHO and stored in the air-conditioned storage unit in accordance with manufacturer’s
instructions (2–28˚C) [Xpert Ebola IVD package insert 301–4826, revision A, June 2015] with
surge capacity stored at WHO warehouse. The cost of the GeneXpert instruments was US$
17,000 each, while that of a single cartridge during this time was US$ 19.80.
Onsite at the ETU two designated independent generators (10kva Kipor and KOH-
LER-SDMO TE Silence) provided 24 hour power supply to the laboratory. Fuel was procured
by WHO requiring approx. 15 gallons per day. Continuous power maintained the air-condi-
tioning and refrigerator enabling daily operations during working hours and stable storage of
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reagents and inactivated samples. Running water was provided by connection to the onsite
ETU water system. Biohazardous waste was collected in biohazardous waste bags, sealed at the
laboratory and brought to the ETU onsite incinerator daily (Alba INCINER8). Due to the
automated cartridge based system the only chemical waste generated was disinfectant solution
which was disposed through the ETU disposal system. Fresh chlorine solution was obtained
daily from the ETU and buckets and a spray can were refilled daily to disinfect all specimen
containers and forms before entering the laboratory. Personal protective equipment, biohazard
bins, biohazard bags, gloves, face shields, bench shields, cleaning supplies and all additional
laboratory supplies were provided by MoH and partners. (S1 Table)
Internet was provided through a mobile 3G modem preloaded with data bundles, sourced
from a Liberian telecommunications company and required approximately 10 USD per week
for operations. A designated laptop, phone and internet connection facilitated daily reporting
of results to the incident management system (IMS) and stakeholders. 24 hour/7 security ser-
vices were available in the form of a night-watch security guard, employed through the ETU. A
designated vehicle and driver were provided by WHO to transport staff between their homes
and the laboratory.
Fig 1. Representation of the layout of the ELWA-III mobile Ebola testing laboratory, at the ELWA Ebola treatment unit, Monrovia.
https://doi.org/10.1371/journal.pntd.0006135.g001
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Human resources and training
In September 2015, six Liberian laboratory technicians were recruited and trained on the Gen-
eXpert diagnostic system at ELWA III laboratory by the regional FIND representative (S1
Text). The week-long training covered technical knowledge and practical skills about the Gen-
eXpert system and Xpert Ebola Assay. Pre- and post-testing were conducted as well as written
and practical evaluation of testing performance to ensure competence and understanding of
the principles of testing, troubleshooting and data management. Bench checklists were pro-
vided to ensure that stock checking, laboratory decontamination and temperature recording
are done daily. Picture aids helped to ensure that testing protocol was followed. On-site super-
visory visits formed a critical part of the quality assurance programme associated with Xpert
Ebola implementation, and were conducted at predetermined time intervals by FIND for early
identification of any problems related to staff, reagents or instruments. Refresher training was
conducted as and when needed. The Laboratory’s Standard Operating Procedures (SOPs) and
work flow were jointly developed and implemented by WHO and ACCEL (S2 Text).
WHO and ACCEL trained laboratory staff on specimen reception and biosafety. WHO and
eHealth Africa (CDC-funded implementing partners) facilitated data management and report-
ing of results including a full-time data manager. Training and supportive supervision for data
management was provided by WHO onsite over the course of a month, with periodic moni-
toring site-visits throughout the operation of the laboratory.
In January 2016, two staff members were supported to attend advanced training through
Cepheid’s High Burden and Developing Countries (HBDC) Training Programme in Toulouse,
France. This specialised training enabled them to serve as “super trainers” responsible for
basic equipment maintenance, troubleshooting, calibration and quality assurance of the Xpert
Ebola test and providing ongoing training and mentoring for other staff. Basic equipment
maintenance was provided by super-trainers as per manufacturers schedule while more
Fig 2. Timeline of key events in establishing and running the ELWA-III mobile EVD testing laboratory—September 2015 to March 2017.
https://doi.org/10.1371/journal.pntd.0006135.g002
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complex equipment maintenance and technical support was provided remotely by FIND’s
regional representative and Cepheid.
Walk-throughs and mock-tests were completed before testing was initiated in September
2015. For all laboratory operations, the buddy-system was adopted whereby two technicians
and the laboratory site manager monitor each other’s safety and remain in constant consulta-
tion throughout the process. In the initial weeks of operation, staff worked on a shift basis over
six days a week, with four staff covering a 12 hour working day. In line with a decreased work-
load in November 2015, working days were reduced to eight hours with two technicians work-
ing in teams on alternate days. The full-time site manager employed by ACCEL oversaw day-
to-day operations. The manager was a local laboratory technician with significant experience
working at the regional EVD reference laboratory in Tappita, Nimba, where he had been
trained in conventional RT-PCR techniques by international laboratory personnel.
During the initial months, daily technical assistance and coordination was provided by
WHO and ACCEL. As laboratory technicians grew in competence and independence the level
of support required reduced. Regular monthly staff meetings were held at the laboratory and
chaired by WHO. In addition, WHO and ACCEL provided assistance in resolving emerging
challenges at the laboratory such as power cuts, addressing equipment errors, sourcing facili-
ties and maintenance technicians and handling specimen rejection, amongst others.
Xpert Ebola assay performance, biosafety and quality assurance
Specimens were delivered to the laboratory either from the ETU or the catchment area by
RFH couriers. All specimens were transported in triple packaging and RFH couriers were
trained on biosafety for handling EVD specimens. Upon arrival at the laboratory plastic con-
tainers were placed in a custom build wooden box in the specimen reception area and forms
received by the laboratory technicians. Containers were disinfected in a bucket of 0.5% hypo-
chlorite for >20mins. Forms were sprayed by a laboratory technician with 0.5% hypochlorite
and allowed to air-dry. Disinfected containers were then transferred to the glove box in the
laboratory where secondary packaging (plastic bags) was removed. Differential pressure in the
glovebox was maintained at 20–50 Pa. Individual specimen tubes were labelled and matched
with the corresponding form which was held outside the glovebox, requiring two technicians
to assign unique laboratory numbers. Forms were then transferred to the office where the data
manager entered all details into the approved MoH EVD laboratory database (Microsoft
Access).
The Xpert Ebola assay was carried out following Cepheid’s instructions [Xpert Ebola IVD
package insert 301–4826, revision A, June 2015]. Briefly, the whole blood specimens were inac-
tivated within the glove box by adding an aliquot/soaked swab of the blood sample to a pre-
labeled vial containing Xpert inactivation buffer. Following a further 20-minute hypochlorite
decontamination step, vials of inactivated blood sample were wiped down with 70% ethanol
and removed from the glovebox. Processing of the sample from this stage onwards was consid-
ered safe on the bench. An aliquot of the inactivated blood sample was then pipetted into the
corresponding pre-labelled, room temperature Xpert cartridge and the test started within 30
minutes using Cepheid’s specifications. The remaining inactivated blood samples were stored
at 4˚C for up to 72 hours in case repeat testing was required. Results were available after 1
hour 30 minutes.
For each test performed, the instrument, system and cartridge contents were monitored
and checked for quality, specifically; sample processing, cartridge reagents, instrument check
and PCR conditions. Two internal controls are included within each cartridge; the, sample
adequacy control (SAC), a human housekeeping gene known as hydroxymethylbilane
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synthase, confirms that sufficient host cellular material was present and detectable in the sam-
ple and the exogenous sample processing control (SPC) controls for PCR inhibition [27].
The probes and primers in this assay detect two structural genes, glycoprotein (GP) and
nucleoprotein (NP) of the EBOV genome. Positive tests were those determined as reactive on
both GP and NP targets by the GeneXpert software. Negative tests were those determined as
non-reactive on both GP and NP targets by the GeneXpert software. A result of invalid was
reported when the assay was processed with errors; either SAC failed, CIC failed, or both SAC
and CIC failed. A result of indeterminate was reported when the assay was processed without
any errors but a specimen could not be determined as positive or negative. This happened
when one target NP or GP was detected without the other; NP detected; GP not detected or
NP not detected; GP detected.
All positive specimens were retested on the GeneXpert system and also transported to the
NRL for confirmation using the US Department of Defence (DOD) EZ1 assay and storage in
the -80 freezer on-site. All invalids were repeated and if a second invalid result was obtained
the specimen was referred to the NRL for confirmation and/or a repeat specimen requested.
Xpert check was carried out weekly to verify optical and thermal functionalities of the
instruments.
Data management and results reporting
Results from the instruments were manually written into a daily worklist corresponding to the
unique laboratory number by the laboratory technician which was then used to transfer results
to the MS access spreadsheet by the data manager. Priority specimen results were phoned
immediately to MoH and WHO Laboratory Coordinators who then informed requesting epi-
demiologist/clinician and stakeholders.
A data manager entered all patient data into the EVD laboratory database as specimens
were received at the laboratory. Results were then matched with the patient information in the
database. At the end of each day the patient and laboratory data were exported into the MoH
reporting template (Microsoft Excel) double-checked and reported to a MoH-approved list of
recipients including IMS members, County health teams (CHT’s) and stakeholders via email.
This information was also uploaded into the WHO EDPLN database which produced WHO
weekly situation reports on the outbreak [36]. Paper records of laboratory specimens and
results, specimen submission forms and laboratory logbooks were stored at the laboratory,
accessible only to authorized personnel.
An SOP for handling priority specimens was developed by the inter-organizational labora-
tory team. During the period of enhanced and thereafter routine EVD surveillance, a specimen
was classified as “priority” when obtained from a presumptive/highly suspect EVD case
through clinical judgement or epi-linkage. Once identified, priority specimens were trans-
ported urgently to the laboratory, triaged and processed immediately and results reported
back by phone to the surveillance or case management teams as soon as available.
Staff feedback
In February 2017, as part of the site close-out activities, a group forum using a short question-
naire was held with the laboratory staff. The intention was to gain an insight into the experi-
ence of the Liberian staff and identify best practices and opportunities for integration in future
operations of mobile laboratories. Key issues explored included level of staff satisfaction while
working at the laboratory, biosafety and security concerns of staff, contribution of the staff to
the Liberian EVD response, opportunities presented by the response, challenges experienced
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in day-to-day work and the significance, if any, of working in a multi-stakeholder collaborative
environment.
Results
Testing capacity and impact on the surveillance system
From its establishment on 28 September 2015 to the end of March 2017 the ELWA laboratory
tested a total of 9,063 blood specimens, including 21 positive from six confirmed cases, 9,039
negative, two indeterminate and one invalid (Fig 3 and Table 1). Operationalisation of the
ELWA laboratory increased the daily testing capacity for EVD in Liberia from 180 to 250 spec-
imens and increased the number of operational EVD laboratories from three to four, provid-
ing diagnostics services in Montserrado county.
From September to November 2015, the ELWA laboratory had the capacity to test up to
100 specimens requiring four technicians and 12 hour working days. Following clearance of
the specimen backlog, laboratory working hours were reduced and the maximum daily capac-
ity was 64 specimens, requiring two technicians working 8 hours per day. The mean specimens
tested per month from September 2015 to August 2016 was 755, ranging from 1663 to 16 (Fig
3). In October 2015, the laboratory processed >1600 specimens to clear the backlog of
untested samples in the laboratory system and to re-establish timely diagnostics to support
EVD surveillance in Liberia. Following the shift to the more specific Integrated Disease Sur-
veillance and Response (IDSR) case definition (Table 2) in August 2016, the numbers of EVD
specimens being taken in the field decreased dramatically (Fig 3). The last specimen was tested
at the laboratory in October 2016 and no samples were received in the last five months of
Fig 3. Number of EVD specimens tested at ELWA III laboratory from initiation of testing in September 2015 to the end of 2016; displaying
Duport Road and Central Monrovia clusters and the impact of the change to IDSR case definition on the numbers of specimens being
processed at the laboratory.
https://doi.org/10.1371/journal.pntd.0006135.g003
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operation. The decision to remain operational from January to March 2017 was to support the
ETU in the event of a re-emergence or reintroduction of EVD.
EVD cluster detection and outbreak response
Following clearance of the backlog (>800) of EVD specimens in early November 2015, a new
case of EVD was identified at ELWA III Laboratory on the 19th November, in a specimen from
a 15-year old boy admitted to the tertiary hospital in Monrovia [37]. The IMS was activated
and the outbreak referred to as the Duport Road cluster [37]. The confirmed case and family
Table 1. No of EVD specimens tested at ELWA III laboratory from September 2015 to the end of 2016, by month of testing and results
interpretation.
Month of Testing Total Samples Tested Sample Interpretation
Negative Positive Indeterminate* Invalid**
2015
Sep 171 171
Oct 1663 1663
Nov 623 613 8 1 1
Dec 403 403
2016
Jan 1149 1149
Feb 992 992
Mar 732 732
Apr 1226 1212 13 1
May 963 963
Jun 885 885
Jul 238 238
Aug 16 16
Sep 0
Oct 1 1
Nov 0
Dec 0
Total 9063 9039 21 2 1
*Indeterminate; NP detected; GP not detected or NP not detected; GP detected
**Invalid; either SAC failed, CIC failed, or both SAC and CIC failed
https://doi.org/10.1371/journal.pntd.0006135.t001
Table 2. Case definition of suspect case of viral haemorrhagic fever as defined in the Integrated Dis-
ease Surveillance and Response (IDSR) Guidelines for Liberia.
Suspected case
Outbreak
setting
Any person (alive or dead) with sudden onset of high fever and at least three of the
following symptoms: headaches, vomiting, anorexia/loss of appetite, diarrhea, lethargy,
stomach pain, aching muscles or joints difficulty swallowing, breath difficulties, hiccups;
OR Any person with acute fever and inexplicable bleeding; OR Any sudden, inexplicable
death; OR Clinical suspicion of VHF OR A person (alive or dead) suffering or having
suffered from a sudden onsite of high fever and having had contact with: a dead or sick
animal (for Ebola); a mine (for Marburg)
Routine setting Any person, alive or dead, with onset of fever and no response to treatment for the usual
causes of fever in the area AND at least one of the following signs: Bloody diarrhea,
bleeding from gums, bleeding into skin (purpura), bleeding into eyes or urine OR clinical
suspicion for Ebola or Marburg Virus Disease
https://doi.org/10.1371/journal.pntd.0006135.t002
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members were transferred to the ETU with two close contacts testing positive upon initial test-
ing. All three cases were admitted to the confirmed ward with other close contacts admitted to
the suspect ward.
In March 2016, the Central Monrovia cluster index case (deceased) was confirmed at the
laboratory and prompt identification of an additional case in this cluster was facilitated.
Patient 2 (CM2) was admitted to the ETU confirmed ward and a number of close contacts
admitted to the suspect ward. Patient 3 (CM3) of the Central Monrovia cluster had been
admitted to the suspect ward for monitoring and had had one negative test when a raise in
temperature prompted re-testing and revealed that the patient had EVD viral RNA in their
blood. The patient was immediately transferred to the confirmed ward to avoid potential
transmission to other patients being held in the suspect ward.
During these periods, several priority specimens were taken in the field or at primary health
care facilities in Montserrado around the response zone. Sample turn-around-time for priority
specimens, from receipt at the laboratory to reporting of results was approx. 2–3 hours. The
system allows for single specimen testing enabling immediate testing of priority specimens
without the need to batch. Line-lists of all confirmed and suspect cases were updated with lab-
oratory results each day, and shared with surveillance and case management teams for discus-
sion at the daily county IMS meeting to ensure implementation of timely and effective
response interventions.
Case management of confirmed cases
During both the Duport Road cluster (Nov/Dec 2015) (3 confirmed cases) and the Central
Monrovia cluster (March/April 2016) (3 confirmed cases), EVD positive patients were moni-
tored regularly by testing repeat specimens at the mobile laboratory. Ct values of consecutive
specimens from EVD positive patients were tracked and compared to indicate trends in the
viral load of patient specimens (Fig 4). This information was used by the case management
team to inform clinical management and discharge decisions. The index cases in both out-
breaks, Patient 1 in the Duport Road cluster (DP 1) and Patient 1 in the Central Monrovia
cluster (MS 1), had very low Ct values, (<25) upon initial testing indicating high viral loads.
Both patients died. Patients 2 and 3 in both clusters (DP 2, 3 and MS 2,3), had higher Ct values
upon initial testing, (>25) and these continued to rise gradually over the course of 2–3 weeks
until eventual recover and discharge. In specimens taken from patient DP 2 and DP 3, the NP
target was detected for longer than the GP target causing results to be reported as indetermi-
nate by the GeneXpert software. Patients were discharged from the ETU once two consecutive
specimens taken 48 hours apart tested negative for both GP and NP targets.
Findings of staff feedback forum
All four of the laboratory technicians reported the overall experience of working at ELWA III
laboratory as very rewarding and they felt very proud of their contribution to the EVD
response in Liberia. All staff members believed that the coordination and collaborative efforts
of partners and stakeholders required to run the laboratory was successful and resulted in very
positive outcomes. Staff described the laboratory environment and the work as both challeng-
ing and rewarding and that the skills and experience gained were beneficial for their future
careers. Overall staff felt valued and supported in their work at the laboratory and benefited
from additional training opportunities which would otherwise not have been available. They
regarded their greatest achievements as identifying the last clusters of EVD cases and helping
to end the outbreak in Liberia. The greatest challenges reported by staff were dealing with the
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specimen backlog upon opening of the laboratory and adapting to working in the confined
space of a mobile laboratory.
Resolving challenges at the mobile facility
The main challenge at the laboratory was the huge workload in the initial months of operation
which required staff to work 12-hour days. In the first weeks the glove box sustained rain dam-
age and was not operational while HEPA filters had to be sourced internationally. This situa-
tion was overcome by processing specimens at the NRL then transferring inactivated samples
to ELWA III for processing on the GeneXperts each day, a process requiring a high level of
coordination and support from staff at the NRL. There was no onsite storage capability for
“live” blood samples; these had to be inactivated upon receipt and stored overnight for next
day processing. Specimens were stable in inactivation buffer refrigerated for >24 hours
according to Cepheid instructions.
As previously reported during the outbreak, biosafety of specimen collection and transport
was not optimal and specimens were often rejected due to inappropriate or unsafe packaging
[20]. Laboratory requisition forms were frequently incorrectly filled in, as a result it was often
challenging to match a laboratory result to the correct patient, many laboratory tests were
reported without a name or identifier, although all were negative. This improved as a unique
patient identifier system was implemented in Liberia, but never fully resolved. To address
these challenges, safe blood specimen collection and packaging training was conducted in the
response zones during both outbreaks and WHO provided blood collection tubes and packag-
ing countrywide throughout the EVD response. County diagnostic officers supported by
WHO field staff in each county were trained and responsible for distribution of supplies and
Fig 4. RT-PCR Ct values for NP and GP gene targets from positive blood samples of EVD cases from
the Duport Road cluster, November-December 2015 and the Central Monrovia cluster, March-April
2016.
https://doi.org/10.1371/journal.pntd.0006135.g004
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quality assurance of specimen collection in their counties. RFH couriers underwent regular
refresher training on good biosafety practices.
Results dissemination of surveillance specimens from central to county and facility level
was an ongoing challenge throughout Liberia. This was addressed by daily reporting directly
from laboratories to CHT’s who were then held accountable for relaying the results to the
respective health facilities at the district level.
Following the switch to IDSR case definition in September 2016 when specimen numbers
declined drastically, a transition plan for ELWA III laboratory was drafted and agreed by MoH
and partners. This outlined redeployment of the instruments, materials and staff from the
ELWA Laboratory to support EVD diagnostics at isolation units in designated health facilities
around the country. Instruments were redeployed to Tellewoyan Hospital, Lofa; Liberian Gov-
ernment Hospital-Tubmanburg, Bomi; ELWA Hospital, Montserrado; Redemption Hospital,
Monrovia. Laboratory technicians were reassigned to facilities around Montserrado and Mar-
gibi counties to support EVD, TB and HIV testing. At the end of 2016 hundreds of cartridges
supplied by FIND based on testing projections, expired and could not be used for EVD testing.
Discussion
WHO, Geneva, initially declared Liberia free of EVD transmission in May 2015 and the country
commenced a 90-day period of heightened surveillance [38]. By this time many international part-
ners supporting the response had scaled down operations or exited Liberia and EVD diagnostic
laboratories had reduced from 10 during the height of the epidemic, to three in June 2015 [22]. Fol-
lowing the Margibi outbreak in June, application of the outbreak EVD case definition and recom-
mendations for heightened surveillance resulted in a surge in the number of EVD specimens being
taken throughout the country. Coupled with the reduction in laboratory capacity, this led to a
build-up of EVD specimens at the laboratories, culminating in significant delays in testing (up to 2
weeks). The consequent lack of visibility in the EVD surveillance system caused significant concern
within IMS and was addressed by a number of measures coordinated by the laboratory team,
including establishment of a mobile laboratory using GeneXpert technology at ELWA ETU.
This unique model describes a mobile laboratory structure co-located at an ETU which dif-
fered from other laboratories deployed during the response in a number of ways [9, 19–21,
39]. The laboratory was equipped with a rapid molecular diagnostic test, Xpert Ebola, allowing
single specimen testing, staffed by local laboratory technicians as opposed to international
teams on short deployments, supported by MoH and a collaboration of international partners,
and provided EVD testing for both surveillance and ETU admissions towards the end of the
outbreak when sustained diagnostic to detect new clusters was essential.
Soon after WHO declared Liberia free of active EVD transmission for the second time on
3rd September 2016 [40], as support from international partners was waning, ELWA III mobile
laboratory was operationalised. The backlog of unanalysed specimens was cleared and real-
time testing capacity restored by the beginning of November 2015. Shortly thereafter, on 19th
November 2015, a new case of EVD was detected at the ELWA III laboratory [37, 41]. On 29th
March 2016 WHO declared the Ebola PHEIC over, but emphasised the importance of main-
taining the capacity and readiness to prevent, detect and respond to any new cases or clusters.
The next day saw confirmation of a new EVD case in Liberia and the Central Monrovia cluster
[42]. During both of these outbreaks the contribution of ELWA laboratory demonstrated the
importance of diagnostic preparedness and the public health impact of rapid diagnostics [7, 9,
43]. This contribution included detection of re-emergence of EVD cases following the declara-
tion of the end of transmission, rapid testing of suspect cases supporting contact tracing and
surveillance activities as well as monitoring confirmed cases admitted to the ETU.
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Constant communication and timely sharing of information between the surveillance
teams operating in the response zones and the laboratory coordination team facilitated effi-
cient testing of suspect cases supporting contact tracing during both responses [14, 37]. Results
of priority specimens requested on suspect cases could be reported within 2–3 hours enabling
implementation of effective response measures [14, 37]. On many occasions, short turn-
around-time to results prevented the need to transfer suspect cases to the ETU allowing
patients to remain in the community or health care facility until a negative result was received
[14, 37]. This reduced disruption to lives of the patients and subsequent costs for transport
and ETU admission [14]. Fallah et al. described how field blood draw combined with Xpert
Ebola diagnostics has the potential to accelerate diagnosis in the emergency setting thereby
reducing transmission and improving chances of recovery [14].
During the Duport Road outbreak, three EVD cases were admitted to ELWA ETU [37] and
in April 2016, the Central Monrovia cluster, two cases were admitted to the confirmed ward
(index case deceased). Co-location of the laboratory onsite at the ETU facilitated rapid testing
of cases which allowed for close monitoring of Ct values, thus providing information on
patient viral load and stage of disease of each patient, important information for contact trac-
ing and case management teams. Interestingly, in both outbreaks the index case had a very low
Ct value (<25) indicating a high viral load at the time of initial testing and neither patient sur-
vived. This phenomenon has been reported previously with low Ct value indicating a high
viral load at the time of detection and possibly more severe or progressed disease with a higher
case fatality rate [19, 21, 29–32, 44]. The collaboration of partners working together under the
coordination of MoH and WHO, enabled a high level of situational awareness and supported
more timely and informed decision-making in particular where additional tests were required,
such as genetic sequencing and serological analysis [14, 37]. In addition, the laboratory
informed patient discharge as well as guiding effective treatment interventions.
As described by Semper, the NP target is often detected for longer than the GP target and in
higher quantities [27]. In our experience, the GeneXpert test called these results indeterminate
(GP not detected, NP detected) and upon retesting at the NRL using the DOD EZ1 RT-PCR
assay were reported negative, indicating the higher sensitivity of the Xpert Ebola assay. Inde-
terminate results were obtained in specimens from confirmed cases who were in the recovery
phase, with viral loads having dropped to almost undetectable levels.
The Xpert assay met a number of the key features outlined by the WHO in their TPP [15,
16, 27, 34, 45] and in our experience confirmed its potential to transform EVD surveillance
and response by shortening the pathway from ordering an EVD test to final diagnosis. The
assay has been shown to have a highly accurate performance and is comparable to other com-
mercial assays for EVD [26, 27, 46]. Running on an automated cartridge-based platform
means the assay has many benefits over conventional PCR platforms including reduced tech-
nical expertise and training requirements, minimal biosafety constraints outside of the glove-
box, less sample processing and a faster turn-around time to results [5, 26, 27, 39]. In Liberia,
the assay resulted in shorter testing time than other EVD testing methodologies including the
DOD EZ1 RT-PCR assay and US CDC’s Ebola virus NP/VP40 RT-PCR assays which were
used in the other three Liberian EVD testing laboratories and averaged at 5–6 hours/run. The
laboratory was operational 6/7 days per week and for 12 hours per day (8am-8pm) for the ini-
tial months. Specimens did not require batching and the system allowed single specimen test-
ing upon receipt at the laboratory. This differed to conventional RT-PCR formats requiring
specimen batching meaning results were often not available until the following day. This was
incredibly beneficial during the EVD outbreak periods and throughout heightened surveil-
lance for testing high priority specimens taken in the field. Co-location with the ETU further
facilitated short turn-around times for confirmed and suspect cases admitted to the ETU
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excluding the need for specimen transport previously described as a bottleneck to rapid diag-
nosis [5]. In Liberia the NRL is located in Margibi county, > 1 hour away from central Monro-
via and on poorly maintained roads highly susceptible to delays for staff and specimen
transport. The decision to locate the ELWA III laboratory at the ETU in Montserrado was
advantageous as it provided EVD diagnostics for the Montserrado catchment area including
the main tertiary hospital in Monrovia and numerous health facilities in the area.
The Xpert Ebola cartridge contains all reagents necessary to conduct the assay including
extraction and amplification, reducing the complexity of the laboratory procedure and allow-
ing for a minimal laboratory infrastructure with sustainable biosafety levels. Allied to this fact,
the laboratory workflow for the Xpert Assay is simpler than conventional RT-PCR approaches
and therefore requires minimal training for laboratory technicians with training in Liberia tak-
ing less than one week, compared with up to three months for conventional RT-PCR methods.
In addition, the cost of the cartridge was US$ 19.80 and cheaper compared to other tests used
in Liberia; ~US$ 21 for DOD EZ1 assay, US$ 185 for the BioFire’s FilmArray cassette and ~US
$ 20 for US CDC Assay. The closed cartridge system of the Xpert Ebola assay means that all
materials for testing are contained within the cartridge thereby simplifying the procurement
process. The stability of the cartridges at room temperature (2–28˚C) allowed for easy delivery
to the site of use and storage onsite in an air-conditioned container without any cold chain
requirements.
The model described here, differs from many mobile laboratories deployed during the out-
break as it was staffed by local laboratory technicians as opposed to international experts on
short missions, providing more sustainable diagnostic capacity, vital as international partner
support declined towards the end of the outbreak [5, 9, 19, 39, 47]. Staff feedback further sup-
ports the success of the laboratory and the impact of the initiative on laboratory systems
strengthening. The level of satisfaction and contribution was very high amongst staff, reporting
a very positive experience. Working at the lab helped them to develop skills and opportunities
to contribute to their future careers as laboratory technicians. They reported feeling valued by
their work supporting the EVD response and believed that they made a significant contribu-
tion to their country. Building such expertise at a local level makes a sustainable contribution
to the health workforce in Liberia.
Despite these significant advantages, the Xpert system nonetheless relies on specialized
equipment, which requires ongoing maintenance and quality assurance. To address this issue
in Liberia, a cohort of six laboratory technicians were supported to attend an advanced train-
ing course at Cepheid, Toulouse in January 2016, including two who worked at ELWA III lab-
oratory. These staff now provide technical support, training and mentoring and routine
monitoring, maintenance and calibration at all GeneXpert sites in the country.
The GeneXpert instrument itself has a small footprint, a further advantage for a mobile lab-
oratory design. While the cost (US$ 17,000) would be prohibitive without donor support the
platforms can be integrated to diagnostic algorithms for a number of diseases of public health
importance, therefore building laboratory capacity.
We agree with Goodfellow et al., that equipment left unused by the local laboratories due to
a lack of training or unsustainability of reagent costs once international teams leave the coun-
try should be avoided [8]. To maximise sustainability of the GeneXpert system in Liberia, an
implementation plan was developed for roll-out of GeneXpert throughout the country to pro-
vide integrated testing for EVD, Human Immunodeficiency virus (HIV) and Tuberculosis
(TB). A Transition Plan for ELWA III Laboratory was developed and implemented outlining
the decommissioning of the laboratory, but recommending that it remain in stand-by mode in
the case of a re-emergence of EVD. The GeneXpert instruments and laboratory staff have been
redeployed to other facilities to support TB and HIV testing to ensure optimum use, impact
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and sustainability of the platforms. The strategic placement of the GeneXpert instruments
aims to complement the establishment of EVD isolation facilities to provide on-site diagnostics
for EVD and also to support TB and HIV clinics. In addition, the potential to connect all
instruments throughout the country to a centrally monitored server add to the attractiveness
from the surveillance perspective.
The establishment of an integrated network of GeneXpert laboratories strengthens epi-
demic preparedness and response capabilities for potential future EVD outbreaks in Liberia.
Laboratory technicians trained as “super-trainers” coordinated and carried out instrument
installation and trainings at additional sites for EVD, HIV and TB testing. ACCEL has pro-
cured a limited number of Ebola Assay kits (~50) to support continuous testing for EVD, but
plans are under way to turn this responsibility over to MoH while cartridges for HIV and TB
testing are supported through Global Fund. FIND and Global Fund support sustainable Gen-
eXpert diagnostics for TB and HIV in the region including Liberia.
There were however a number of limitations associated with the GeneXpert laboratory
model. Firstly, the assay had not been validated for use with body fluids other than whole
blood which was a limitation in Liberia where a significant proportion of samples taken in the
field were oral swabs from dead bodies. Guidelines for testing additional specimen types
should be developed and field tested [7]. Secondly, as outlined by WHO in the TPP for safe,
rapid, and cost-effective EVD diagnostic tests and discussed by Broadhurst et al, desired char-
acteristics include minimal power requirements and maintenance needs [7, 15]. The GeneX-
pert system relies on specialised equipment, a computer, air conditioning and operational
glovebox for specimen processing, therefore requires access to uninterrupted power as well as
expertise in instrument maintenance, calibration and repair. Thirdly, specimens could not be
stored at the laboratory and all positive specimens were transferred to the NRL for storage
while negatives were discarded.
The shelf-life of the cartridges when testing commenced in Liberia was only three months
however this was extended by Cepheid upon request after additional quality control data
became available. Cepheid have committed to maintaining a stock of Xpert Ebola reagents,
though new test lots in future outbreaks may have similar issues. In addition, the unanticipated
drop in specimen numbers correlating with the change to the IDSR case definition in August
2016 resulted in hundreds of unused cartridges expiring in late 2016. Improved management
of stock and supplies is an important learning experience from this project. EQA panels were
not available for proficiency testing during the outbreak and development of low cost panels
should be considered for future epidemics.
Conclusion
EVD remains a threat in West Africa and this may not be the last epidemic in this area [8].
The GeneXpert system requires minimal training, limited laboratory infrastructure, procure-
ment of only reagent kits, no cold-storage and can run on a generator. The training of local
Liberian staff on the platform has contributed towards strengthening the laboratory system in
Liberia for EVD and other disease of public health importance. The combination of GeneXpert
technology and the mobile laboratory unit allows for the rapid deployment of diagnostics
within ETU’s or isolation facilities, a previously reported bottleneck during the early stages of
the outbreak in 2014 [43]. This co-location significantly improves the turnaround time from
specimen collection to reporting of results and thereby triggers timely ETU admission of con-
firmed cases and implementation of response interventions. The short turnaround time sup-
ports efficient contact tracing by rapid testing of priority specimens and informs case
management through real-time monitoring of patient viral load to inform clinical
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management and discharge decisions [5, 19, 21, 30, 32]. We propose that the model described
here serves to strengthen outbreak preparedness and response for future outbreaks of EVD in
Liberia and the region.
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